View More Recent Stories
-
ROSEN, A LONGSTANDING LAW FIRM, Encourages Geron Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - GERN
-
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Geron Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - GERN
-
GERN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Geron Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
GERN INVESTOR NOTICE: Geron Corporation Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
-
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron
-
ROSEN, NATIONAL TRIAL ATTORNEYS, Encourages Geron Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - GERN
-
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Geron Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - GERN
-
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Geron Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - GERN
-
GERN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Geron Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
ROSEN, A TOP RANKED LAW FIRM, Encourages Geron Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - GERN
-
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Geron Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - GERN
-
ROSEN, A LEADING LAW FIRM, Encourages Geron Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - GERN
-
GERN INVESTOR DEADLINE: Geron Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
ROSEN, A RANKED AND LEADING FIRM, Encourages Geron Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - GERN
-
GERN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Geron Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
Geron Corp (GERN) announces inducement grants for new employees
-
ROSEN, A LEADING LAW FIRM, Encourages Geron Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - GERN
-
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron
-
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Geron Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - GERN
-
GERN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Geron Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Geron Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - GERN
-
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron
-
GERN ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Geron Corporation Investors
-
H.C. Wainwright Reiterates Neutral Rating on Geron Corporation (GERN)
-
Geron Corp (GERN) Announces European Commission Approval of RYTELO
-
Geron Corp (GERN) announces departure of CEO John Scarlett
-
Geron Corporation (GERN) PT Lowered to $4 at Stifel
-
Geron Corporation (GERN) PT Lowered to $4 at Scotiabank
-
Geron Corporation (GERN) PT Lowered to $5 at TD Cowen
-
H.C. Wainwright Downgrades Geron Corporation (GERN) to Neutral
-
Geron Corp (GERN) Misses Q4 EPS by 1c ; Provides Outlook
-
Geron Corporation (GERN) PT Lowered to $3.50 at B.Riley
-
Geron Corp (GERN) Received Positive CHMP Opinion for RYTELO
-
Stifel Reiterates Buy Rating on Geron Corporation (GERN)
-
Geron Corp (GERN) Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies
-
Geron Corp (GERN) Appoints Joseph Eid as EVP, R&D
-
Geron Corp (GERN) Tops Q3 EPS by 4c
-
Royalty Pharma plc (RPRX) to Acquire Royalty Interest in Geron’s (GERN) RYTELO for $125M
-
Geron Corp (GERN) Announces Up to $375M in Funding with Royalty Pharma and Pharmakon Advisors
-
H.C. Wainwright Starts Geron Corporation (GERN) at Buy
-
B.Riley Reiterates Buy Rating on Geron Corporation (GERN) ahead of Q3
-
Leerink Partners Reiterates Outperform Rating on Geron Corporation (GERN)
-
Goldman Sachs on Geron Corporation (GERN): 'We are encouraged by the update, as it reflects GERN's continued commercial execution on the launch of the agent'
-
Goldman Sachs Reiterates Buy Rating on Geron Corporation (GERN)
-
Geron Corp (GERN) Appoints Jim Ziegler as Chief Commercial Officer
-
Leerink Partners Starts Geron Corporation (GERN) at Outperform, 'We estimate peak US Rytelo sales in LR-MDS of ~$1.4B'
-
Geron Corp (GERN) Announces Updated NCCN Guidelines Recommending RYTELO for the Treatment of Symptomatic Anemia in Patients with Lower-Risk MDS
-
Geron Corp (GERN) Announces Upcoming Departure of Chief Commercial Officer
-
Geron Corporation (GERN) PT Raised to $6 at Goldman Sachs
-
Geron Corporation (GERN) PT Raised to $7 at Stifel
